{"disease":{"id":"non-q-wave-myocardial-infarction","name":"Non-Q wave myocardial infarction","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"heparin","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in non-Q-wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"tirofiban","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aggrastat","generic_name":"TIROFIBAN","company_name":"Medicure","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor","quality_score":75,"revenue":null,"mechanism":"Aggrastat works by blocking the integrin alpha-IIb/beta-3 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"heparin-sodium","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"eptifibatide","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Integrilin","generic_name":"EPTIFIBATIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots."},{"drug_id":"clopidogrel","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"integrilin","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"integrilin","company_name":"University of Cincinnati","drug_phase":"phase_1","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave myocardial infarction","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave myocardial infarction","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-preservative-free","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave MI","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-preservative-free","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave MI","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave MI","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium","guideline_body":"FDA label","recommendation":"Prevention of ischemic complications of non-Q wave MI","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}